Abstract
Acute myeloid leukemia (AML) is a group of hematologic malignancy with high heterogeneity. Old people are at a high risk of AML with poor outcome, while compared with younger ones, chemotherapy of elderly patients were always limited by some conditions associated with aging, such as organ dysfunction, debility and more comorbidities. This article reviews the new advances in treatment of elderly AML in recent years, to provide reference on characteristics of elderly AML, evaluations of prognosis in elderly patients with AML, as well as treatment decision making. Key words: Leukemia, myeloid, acute; Elderly; Drug therapy, combination; Prognosis; Drugs, investigational
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
